ovarian neoplasms, ovary tumour, ovary, fallopian tube, primary peritoneal, cancer, neoplasm, adenocarcinoma, carcinoma, malignant, tumour, metastases, drug therapy, antineoplastic agent, chemotherapy, adjuvant chemotherapy, consolidation chemotherapy, antineoplastic combined chemotherapy protocols, molecular targeted therapy, systemic, biologic, targeted, immunotherapy, hormone, maintenance, therapy, treatment, adriamycin, carboplatin, cisplatin, platinum, platamin, neoplatin, cismaplat, cis-diamminedichloroplatinum, cisdiamminedichloroplatinum, cyclophosphamide, doxorubicin, epirubicin, gemcitabine, irinotecan, isosfamide, paclitaxel, taxane, etoposide, platinum, MEK inhibitor, PD-325901, selumetinib, AZD6244, PD184352, CI-1040, PD035901, TAK-733, binimetinib, MEK162, ARRY-162, ARRY-438162, trametinib, GSK1120212, mekinist, cobimetinib, cotellic, XL518, GDC-0973, poly(ADP-ribose) polymerase inhibitors, olaparib, AZD2281, lynparza, AZD221, veliparib, ABT888, talazoparib, BMN673, nintedanib, iniparib, oregovomab, abagovomab, CA-125, MUC 16, pazopanib, niraparib, MK4827, rucaparib, PF-01367338, AG014699, rapamune, rapamycin, sirolimus, I2190A, AY 22989, cediranib, recentin, AZD2171, antibodies, monoclonal, humanized, bevacizumab, avastin, mTOR inhibitor, temsirolimus, CCI 779, torisel, everolimus, afinitor, certican, RAD001, SDZ-RAD, deforolimus, ridaforolimus, MK8669, AP23573, BRAF inhibitor, PLX8394, vemurafenib, RG7204, R05185426, PLX4032 or PLX-4032, zelboraf, dabrafenib, tafinlar, GSK2118436, tumour-infiltrating lymphocyte therapy, cytokines, IL-2, interferon, IFN-alpha, immune checkpoint inhibitor, thalidomide, sedoval, thalomid, revlimid, lenalidomide, CC5013, S-3APG, pomalidomide, pomalyst, imnovid, CC-4047, bacille calmette-guerin, tamoxifen, tomaxithen, zitazonium, soltamox, novaldex, nolvadex, ICI47699, ICI46474, fareston, fulvestrant, faslodex, ZM 182780, ICI182780, letrozole, femara, CGS-20267, anastrozole, arimidex, ICI D1033, ZD-1033, examestane, aromasin, FCE-24304, cystorelin, dirigestran, factrel, GnRH, gonadoliberin, luliberin, gonadotropin-releasing hormone, kryptocur, LFRH, luteinizing hormone-releasing hormone, angiogenesis inhibitor, aromatase inhibitor, topotecan, hycamtamine, NSC-609699, SKF104864A, oxaliplatin, eloxatin, docetaxol, taxotere, RP-56976, trabectedin, ecteinascidin, yondelis, ET-743, NSC 684766
The library contains links to guidelines published or endorsed by GIN member organisations from across the globe. It also contains a registry of planned guidelines and guidelines in development. Non members are actively encouraged to register their guidelines in development. Contact library@g-i-n.net to find out how. To learn more about GIN and membership, click the website button above.